An article published by Merlin researchers from UNIPD has recently been published in the “Leukemia” journal. The piece is entitled “Mouse mesenchymal stem cells inhibit high endothelial cell activation and lymphocyte homing to lymph nodes by releasing TIMP-1” (Author(s): Zanotti L, Angioni R, Calì B, Soldani C, Ploia C, Moalli F, Gargesha M, D’Amico G, Elliman S, Tedeschi G, Maffioli E, Negri A, Zacchigna S, Sarukhan A, Stein JV, Viola A) and appears in the May issue. The article deals with the impact of MSC on immunity and inflammation and identifies TIMP-1 as a novel biomarker for MSC-based therapy. You can access the article here.
- The @FP7Merlin #clinicaltrial: NOW RECRUITING It is designed to: i) Determine dose safety of ORBCEL-C (selected Me… t.co/DNXAZmFZeK Time ago 23 Days via Twitter Web Client
- RT @unibirm_MDS: Project MERLIN, a new trial coordinated by @CRCTU @ImmunologyUoB, is recruiting up to 56 patients to investigate the safet… Time ago 34 Days via Twitter for iPhone
- RT @unibirm_MDS: A new cell therapy for chronic #liverdisease is being trialled as part of @fp7merlin by @CRCTU @ImmunologyUoB. It’s hoped… Time ago 38 Days via Twitter for iPhone
Follow @fp7merlin on twitter.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602363. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.